Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEO22
- Development stage
- Preclinical
- Lead developer
- Neobe Therapeutics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
NEO22 is an engineered live biotherapeutic product (LBP) developed by Neobe Therapeutics. It consists of a nonpathogenic bacterial strain (specifically engineered Escherichia coli) designed to colonize solid tumors and express hyaluronidase under a hypoxia-inducible promoter. Rather than directly killing cancer cells, NEO22 degrades hyaluronic acid (hyaluronan) within the dense extracellular matrix (ECM) of the tumor microenvironment. This enzymatic breakdown reduces tumor stiffness, improves vascular functionality, and enhances the infiltration and efficacy of co-administered immunotherapies, such as immune checkpoint inhibitors or CAR-T cell therapies.
Beyond the preview
Go deeper on NEO22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEO22.
Work on NEO22? Claim this page to correct or add information. Claim this page